BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38104908)

  • 21. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
    Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
    Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
    Mergener S; Siveke JT; Peña-Llopis S
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current molecular and clinical insights into uveal melanoma (Review).
    Fallico M; Raciti G; Longo A; Reibaldi M; Bonfiglio V; Russo A; Caltabiano R; Gattuso G; Falzone L; Avitabile T
    Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BAP1 germline mutation in two first grade family members with uveal melanoma.
    Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
    Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer.
    Boru G; Grosel TW; Pilarski R; Stautberg M; Massengill JB; Jeter J; Singh A; Marino MJ; McElroy JP; Davidorf FH; Cebulla CM; Abdel-Rahman MH
    Genes Chromosomes Cancer; 2019 Sep; 58(9):650-656. PubMed ID: 30883995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 8q Gain Has No Additional Predictive Value in
    Nguyen JQN; Drabarek W; Vaarwater J; Yavuzyigitoglu S; Verdijk RM; Paridaens D; Naus NC; de Klein A; Brosens E; Kiliç E;
    Ophthalmol Sci; 2024; 4(2):100413. PubMed ID: 38187129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
    Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
    Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines.
    Refaian N; Schlereth SL; Koch KR; Notara M; Hos D; Mescher M; Iden S; Bosch JJ; Jager MJ; Cursiefen C; Heindl LM
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5691-7. PubMed ID: 26313304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
    Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
    Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of nm23-H1 in uveal melanoma.
    Bakalian S; Marshall JC; Faingold D; Logan P; Antecka E; Burnier MN
    Melanoma Res; 2007 Oct; 17(5):284-90. PubMed ID: 17885583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
    García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.
    Chua V; Orloff M; Teh JL; Sugase T; Liao C; Purwin TJ; Lam BQ; Terai M; Ambrosini G; Carvajal RD; Schwartz G; Sato T; Aplin AE
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30610113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
    Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
    Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of microRNA-130a represses uveal melanoma cell migration and invasion through inactivation of the Wnt/β-catenin signaling pathway by downregulating USP6.
    Wu S; Han M; Zhang C
    Cancer Gene Ther; 2022 Jul; 29(7):930-939. PubMed ID: 34522027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.
    Weidmann C; Bérubé J; Piquet L; de la Fouchardière A; Landreville S
    Clin Exp Metastasis; 2018 Mar; 35(3):123-134. PubMed ID: 29696577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma.
    Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W
    ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
    Wan Q; Sang X; Jin L; Wang Z
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
    Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
    Amirouchene-Angelozzi N; Nemati F; Gentien D; Nicolas A; Dumont A; Carita G; Camonis J; Desjardins L; Cassoux N; Piperno-Neumann S; Mariani P; Sastre X; Decaudin D; Roman-Roman S
    Mol Oncol; 2014 Dec; 8(8):1508-20. PubMed ID: 24994677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.